Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Dermatologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Guidelines for the management of vitiligo: the European Dermatology Forum consensus.Br J Dermatol. 2013; 168: 5-19
- A review of the worldwide prevalence of vitiligo in children/adolescents and adults.Int J Dermatol. 2012; 51: 1206-1212
- Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985.Med J Aust. 2006; 184: 6-10
- Sun exposure, sun protection, and vitamin D.JAMA. 2005; 294: 1541-1543
- Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.Am J Prev Med. 2015; 48: 183-187
- Some aspects of melanin biology: 1950-1975.J Invest Dermatol. 1976; 67: 72-89
- Skin cancer in skin of color.J Am Acad Dermatol. 2006; 55 ([quiz: 61–4]): 741-760
- Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.N Engl J Med. 2010; 362: 1686-1697
- Genome-wide association study identifies three loci associated with melanoma risk.Nat Genet. 2009; 41: 920-925
- Association of vitiligo with HLA-A2: a meta-analysis.J Eur Acad Dermatol Venereol. 2007; 21: 205-213
- Melanoma-associated leukoderma - immunology in black and white?.Pigment Cell Melanoma Res. 2013; 26: 796-804
- Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.J Am Acad Dermatol. 2013; 69: e28-e29
- Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.J Cutan Pathol. 2016; 43: 787-791
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.JAMA Dermatol. 2016; 152: 45-51
- CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance.J Exp Med. 2009; 206: 421-434
- Immune Checkpoint Blockade in Cancer Therapy.J Clin Oncol. 2015; 33: 1974-1982
- Vitiligo: the white armour?.Pigment Cell Melanoma Res. 2013; ([Epub ahead of print])
- A clinical trial and molecular study of photoadaptation in vitiligo.Br J Dermatol. 2009; 160: 534-539
- 311 nm tolerance of vitiligo skin increases with skin photo type.Acta Derm Venereol. 2005; 85: 24-26
- Clinical practice. Vitiligo.N Engl J Med. 2009; 360: 160-169
- A new development in UVB phototherapy of psoriasis.Br J Dermatol. 1988; 119: 11-19
- 311 nm UVB phototherapy–an effective treatment for psoriasis.Br J Dermatol. 1988; 119: 691-696
- Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.Arch Dermatol. 2007; 143: 578-584
- Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.Arch Dermatol. 1997; 133: 1525-1528
- Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo.J Eur Acad Dermatol Venereol. 2006; 20: 175-177
- Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.Br J Dermatol. 2008; 159: 931-935
- No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study.Acta Derm Venereol. 2004; 84: 370-374
- Chronic cutaneous effects of long-term psoralen and ultraviolet radiation therapy in patients with vitiligo.Natl Cancer Inst Monogr. 1984; 66: 191-196
- PUVA treatment of vitiligo: a retrospective study of 59 patients.Acta Derm Venereol. 1992; 72: 305-306
- Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo.Arch Dermatol. 1995; 131: 734-735
- Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations.Paediatr Drugs. 2013; 15: 303-310
- Topical tacrolimus for atopic dermatitis.Cochrane Database Syst Rev. 2015; (CD009864)
- Vitiligo and cutaneous melanoma. A case study.Dermatologica. 1991; 183: 239-245
- Vitiligo in patients with metastatic melanoma: a good prognostic sign.J Am Acad Dermatol. 1983; 9: 689-696
- Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo.J Am Acad Dermatol. 2009; 60: 929-933
- Prediction of the Occurrence of Melanoma and Non-melanoma Skin Cancer in Patients with Vitiligo.Acta Derm Venereol. 2016; 96: 106-107
- On the association between vitiligo and malignant melanoma.Acta Derm Venereol. 1998; 78: 483-484
- Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed caucasian patients with vitiligo.Dermatology. 2002; 204: 194-201
- Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners.Br J Dermatol. 2013; 168: 162-171
- Long-term prognosis of vitiligo patients on narrowband UVB phototherapy.J Am Acad Dermatol. 2012; 66: 326-327
- Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo.J Am Acad Dermatol. 2014; 71: 1110-1116
- UVB phototherapy and skin cancer risk: a review of the literature.Int J Dermatol. 2005; 44: 355-360
- Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin.Dermatologica. 1987; 174: 266-271
- Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage.FASEB J. 2009; 23: 3790-3807
- Increased epidermal functioning wild-type p53 expression in vitiligo.Exp Dermatol. 2003; 12: 268-277
- Nonmelanoma skin cancer in vitiligo patients.J Am Acad Dermatol. 2009; 61: 1080-1081
- Why vitiligo is associated with fewer risk of skin cancer?: providing a molecular mechanism.Arch Dermatol Res. 2011; 303: 623-624
Article info
Footnotes
Disclosures: The author has no conflicts of interest to declare.
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
